Why the study?
What are the risk factors and comparative risks of gastrointestinal bleeding in patients receiving new oral anticoagulants versus warfarin?
What are the risk factors and comparative risks of gastrointestinal bleeding in patients receiving new oral anticoagulants versus warfarin?
This review highlights that while NOACs offer advantages over warfarin, specific agents like dabigatran and rivaroxaban carry a higher risk of GI bleeding, which is exacerbated by factors like age, organ dysfunction, and concurrent interacting medications.
GI bleeding risk with NOACs varies by agent and dose; leaves open optimal selection in AF pending higher-level data.
No takes yet. Share an insight, caveat, or question.
Ju Yup Lee (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: